Predicted protein targets (top 15)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LMNA | P02545 | 3/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 3/20 | 0.39 |
| ▸ | HTT | P42858 | 2/20 | 0.37 |
| ▸ | MEN1 | O00255 | 1/20 | 0.36 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.34 |
| ▸ | MERTK | Q12866 | 1/20 | 0.33 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.32 |
| ▸ | AHR | P35869 | 1/20 | 0.31 |
| ▸ | MAPT | P10636 | 1/20 | 0.31 |
| ▸ | NTRK1 | P04629 | 1/20 | 0.31 |
| ▸ | JAK2 | O60674 | 1/20 | 0.30 |
| ▸ | LRRK2 | Q5S007 | 1/20 | 0.30 |
| ▸ | SYK | P43405 | 1/20 | 0.30 |
| ▸ | NPC1 | O15118 | 1/20 | 0.30 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4687405 | 0.83 | LMNA (0.39) | LMNAKDM4EHTTMEN1KMT2A | |
| SCHEMBL24177973 | 0.77 | KMT2A (0.42) | LMNAKDM4EHTTMEN1KMT2A | |
| SCHEMBL5402443 | 0.77 | LRRK2 (0.50) | LMNAKDM4EHTTMEN1KMT2A | |
| SCHEMBL5416240 | 0.74 | LMNA (0.43) | LMNAKDM4EHTTMEN1KMT2A | |
| SCHEMBL15785397 | 0.74 | LMNA (0.40) | LMNAKDM4EHTTMEN1KMT2A | |
| SCHEMBL27470316 | 0.73 | MERTK (0.35) | LMNAKDM4EHTTMEN1KMT2A | |
| SCHEMBL5407989 | 0.73 | LMNA (0.42) | LMNAKDM4EHTTMEN1KMT2A | |
| SCHEMBL12876461 | 0.73 | KDM4E (0.42) | LMNAKDM4EHTTMEN1KMT2A | |
| SCHEMBL28300418 | 0.73 | KDM4E (0.42) | LMNAKDM4EHTTMEN1KMT2A | |
| SCHEMBL27495000 | 0.73 | LMNA (0.42) | LMNAKDM4EHTTMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1560829-B1 | PYRIMIDO COMPOUNDS HAVING ANTIPROLIFERATIVE ACTIVITY (II) | HOFFMANN LA ROCHE (CH) | 2008-02-20 | — | — | EP | disclosed |
| US-7129351-B2 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. (US) | 2006-10-31 | — | — | US | disclosed |
| US-20040110773-A1 | Pyrimido compounds having antiproliferative activity | HOFFMANN-LA ROCHE INC. | 2004-06-10 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040110773-A1 | Pyrimido compounds having antiproliferative activity | SRC, LYN, TK1 | LMNA 4843/4885KDM4E 2418/4885HTT 3187/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.